Valuation: Black Diamond Therapeutics, Inc.

Market Cap 104M 90.91M 84.03M 77.28M 146M 10B 148M 1B 394M 4.89B 389M 381M 16.86B P/E 2026 *
-2.79x
P/E 2027 * -1.8x
Enterprise Value 104M 90.91M 84.03M 77.28M 146M 10B 148M 1B 394M 4.89B 389M 381M 16.86B EV / Sales 2026 *
18.7x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 104M
+0.24%-0.79%+56.36%+53.56% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+1.46%+1.62%+38.64%-4.62% 20.03B
-0.58%-0.91%+32.45%-33.80% 17.31B
-1.67%-6.00%+163.95%+284.69% 14.99B
+1.49%+2.67%+35.46%+586.58% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
Average +0.51%-0.71%+43.36%+170.86% 26.29B
Weighted average by Cap. +1.27%-0.93%+43.09%+133.41%

Financials

2026 *2027 *
Net sales 5.56M 4.87M 4.5M 4.14M 7.81M 536M 7.94M 53.82M 21.1M 262M 20.86M 20.41M 903M -
Net income -40.47M -35.47M -32.79M -30.16M -56.9M -3.9B -57.82M -392M -154M -1.91B -152M -149M -6.58B -70.04M -61.39M -56.75M -52.19M -98.48M -6.75B -100M -679M -266M -3.3B -263M -257M -11.39B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.810USD
Average target price
9.857USD
Spread / Average Target
+444.59%

Quarterly revenue - Rate of surprise